Form 8-K · Current Report · Filed 2025-06-18
Regeneron Pharmaceuticals Shareholder Voting Results Announced
Regeneron Pharmaceuticals, Inc. disclosed the voting results of its 2025 Annual Meeting of Shareholders held on June 13, 2025. Shareholders elected four new directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm, approved the compensation of named executive officers on an advisory basis, and approved the declassification of the board of directors. However, two proposals to amend the Certificate of Incorporation to eliminate supermajority vote requirements were not approved.
- Filer
- Regeneron Pharmaceuticals, Inc. REGN · NASDAQ
- Filed
- Accession
- 0001104659-25-060637
- CIK
- 0000872589
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Submission of Matters to a Vote of Security Holders
Market reaction
Close before filing
$508.86
Next session
+0.2%
Since filing
+49.9%
Latest close
$762.63
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from REGN reporting the same item, with the next session's move:
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Never miss another REGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.